Last reviewed · How we verify
GADOFOSVESET TRISODIUM
GADOFOSVESET TRISODIUM is a drug. It is currently FDA-approved (first approved 2005).
At a glance
| Generic name | GADOFOSVESET TRISODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2005 |
Approved indications
Common side effects
Key clinical trials
- Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases (PHASE2)
- Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent (PHASE3)
- Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease (PHASE4)
- Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
- Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI) (PHASE4)
- Gadofosveset Trisodium for Heart Imaging Studies
- Imaging of Totally Blocked Arteries (PHASE1)
- Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GADOFOSVESET TRISODIUM CI brief — competitive landscape report
- GADOFOSVESET TRISODIUM updates RSS · CI watch RSS
Frequently asked questions about GADOFOSVESET TRISODIUM
What is GADOFOSVESET TRISODIUM?
GADOFOSVESET TRISODIUM is a Small molecule drug.
When was GADOFOSVESET TRISODIUM approved?
GADOFOSVESET TRISODIUM was first approved on 2005.
What development phase is GADOFOSVESET TRISODIUM in?
GADOFOSVESET TRISODIUM is FDA-approved (marketed).